Yahoo · Oct 14, 2026
SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals
J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.
NASDAQ · JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$248.61
Up+$3.16 (+1.27%)
Updated Oct 14, 2026, 4:14 PM
SID Score
7.3/10
Composite research score
Smart Money
50/100
Neutral
- Market cap
- 505.78B
- P/E ratio
- 20.3
- Dividend yield
- 2.07%
- 52-week range
- $200.91 – $281.07
- Volume
- 16.65M
- Avg. volume
- 8.82M
Price performance · JNJ
JNJ price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
JNJ closed at $248.61 after 21 trading sessions, down 6.96% for the selected period.
- Last close
- $248.61
- Period change
- -6.96%
- Period low
- $248.61
- Period high
- $271.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $254.56 | $256.1822 | $245.17 | $248.61 | 16.65M |
| Oct 12, 2026 | $261.60 | $264.39 | $260.3685 | $263.73 | 5.91M |
| Oct 9, 2026 | $255.09 | $261.61 | $254.985 | $261.44 | 5.73M |
| Oct 8, 2026 | $256.22 | $257.80 | $251.945 | $256.48 | 6.18M |
| Oct 7, 2026 | $256.21 | $260.68 | $255.73 | $258.45 | 5.41M |
| Oct 6, 2026 | $254.15 | $255.48 | $251.17 | $254.78 | 5.66M |
| Oct 5, 2026 | $256.00 | $256.24 | $252.51 | $252.93 | 10.03M |
| Oct 2, 2026 | $259.38 | $259.38 | $255.12 | $256.03 | 10.94M |
| Oct 1, 2026 | $263.68 | $263.975 | $258.33 | $258.66 | 8.29M |
| Sep 30, 2026 | $267.91 | $268.48 | $264.51 | $264.74 | 6.34M |
| Sep 29, 2026 | $269.11 | $271.894 | $265.5883 | $267.57 | 5.62M |
| Sep 28, 2026 | $270.17 | $273.78 | $269.27 | $271.95 | 7.19M |
| Sep 25, 2026 | $271.70 | $272.2459 | $269.2573 | $271.22 | 4.09M |
| Sep 24, 2026 | $269.52 | $275.23 | $269.01 | $270.68 | 6.32M |
| Sep 23, 2026 | $269.47 | $272.14 | $266.50 | $269.17 | 6.64M |
| Sep 22, 2026 | $267.51 | $270.10 | $265.04 | $269.19 | 5.68M |
| Sep 21, 2026 | $271.74 | $273.73 | $268.50 | $269.47 | 4.49M |
| Sep 18, 2026 | $269.45 | $272.11 | $267.1975 | $269.99 | 16.43M |
| Sep 17, 2026 | $268.00 | $270.87 | $267.11 | $270.22 | 6.57M |
| Sep 16, 2026 | $266.81 | $268.65 | $266.295 | $267.28 | 4.89M |
| Sep 15, 2026 | $265.81 | $267.20 | $260.68 | $267.20 | 5.28M |
Latest JNJ news
The latest Smart Investors Daily articles mentioning JNJ.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JNJ research
Overview
Company profile and research snapshot.
Company profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $207.08
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Guggenheim | Buy | — |
| Oct 6, 2026 | RBC Capital | Outperform | — |
| Oct 5, 2026 | Citigroup | Buy | — |
| Sep 29, 2026 | JP Morgan | Neutral | — |
| Sep 10, 2026 | HSBC | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 14, 2026
J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks?
The J&J selloff shows how medtech weakness can outweigh pharma strength, and what it means for healthcare stocks.
Yahoo · Oct 13, 2026
J&J (JNJ) Q3 2026 Earnings Call Transcript
Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.
Yahoo · Oct 13, 2026
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what
AI research layers
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson Stock Performance
Johnson & Johnson shares closed at $248.61, reflecting a daily decline of 0.38% per SID market data. Over the trailing one-month period, the stock has edged down 0.7%, though three-month and one-year returns remain positive at 3.89% and 26.93%, respectively. The stock currently trades below its 50-day moving average of $265.48, representing a discount of approximately 6.4%, while hovering just above its 200-day moving average of $246.91. The 14-day relative strength index stands at 42.5, indicating the stock is approaching oversold territory without yet triggering a definitive signal. Average daily trading volume registers at approximately 8.82 million shares, according to Massive/Polygon data. Johnson & Johnson maintains a beta of 0.349, underscoring its historically low volatility relative to the broader market — a characteristic consistent with its defensive healthcare sector positioning and diversified business model.
Johnson & Johnson Valuation Analysis
Johnson & Johnson carries a market capitalization of approximately $505.78 billion, making it one of the largest healthcare companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 20.30, which aligns closely with the broader healthcare sector median. Its PEG ratio of 1.91 suggests the current valuation accounts for moderate earnings growth expectations, according to SEC filings and consensus estimates. The price-to-book ratio stands at 6.43, reflecting the premium typically assigned to companies with strong brand portfolios and intellectual property assets. Johnson & Johnson offers a dividend yield of 2.45%, reinforcing its reputation as a reliable income-generating investment. The company is a Dividend King with over six decades of consecutive annual dividend increases. These valuation metrics collectively position Johnson & Johnson as a moderately valued large-cap healthcare name, balancing growth potential with income stability for shareholders.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score stands at 50 out of 100, reflecting a neutral signal overall, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating strong conviction among large fund managers and asset allocators. In contrast, insider activity scores 8.8 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days — comprising 8 purchases and 12 sales. The net selling bias among insiders suggests executives have been trimming positions, though such activity can reflect routine diversification rather than bearish conviction. Dark pool activity registers at 9.5 out of 25, pointing to below-average institutional accumulation through off-exchange venues. Congressional trading scores 7.0 out of 25, per 13F institutional filings and disclosure records. The divergence between high institutional confidence and weaker insider and dark pool signals creates a mixed smart money landscape, warranting continued monitoring of filing activity.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated a consistent trend of meeting or exceeding analyst expectations across recent quarters, according to company earnings reports. In the most recent quarter, the company reported earnings per share of $2.59 against a consensus estimate of $2.53, delivering a positive surprise of $0.06. The prior quarter showed EPS of $2.90 versus the $2.85 estimate, a $0.05 beat. The streak extends back three consecutive quarters of outperformance, with the April report posting $2.70 against a $2.67 estimate. The sole miss in the four-quarter window occurred in January, when actual EPS of $2.46 fell $0.01 short of the $2.47 consensus, per analyst estimates. Sequential earnings growth from $2.46 to $2.90 across the reported quarters reflects a trajectory of improving profitability. This pattern of modest but reliable beats reinforces Johnson & Johnson's reputation for operational predictability among large-cap healthcare peers.
Wall Street Analyst Ratings for JNJ
Wall Street consensus on Johnson & Johnson remains predominantly constructive, with recent analyst actions skewing bullish, per Wall Street analyst reports. On October 7, Guggenheim reiterated a Buy rating, while RBC Capital maintained its Outperform rating on October 6. Citigroup also reaffirmed a Buy rating on October 5, and HSBC upheld its Buy rating on September 10, according to SID consensus data. The lone neutral stance among recent coverage comes from JP Morgan, which maintained its Neutral rating on September 29. Notably, none of the five most recent analyst actions involved a downgrade or a shift to a negative posture — all were reiterations of existing positions. This suggests that despite the stock's recent pullback below its 50-day moving average at $265.48, covering analysts have not altered their fundamental thesis. The clustering of Buy-equivalent ratings from four of five major banks reflects broad institutional confidence in Johnson & Johnson's forward trajectory.
